Aptargroup - ATR STOCK NEWS

Aptar Pharma, a leader in drug delivery systems and part of AptarGroup (NYSE: ATR), has launched the APF Futurity nasal spray pump, the first metal-free, multidose nasal spray designed for over-the-counter formulations. This pump, certified as highly recyclable by cyclos-HTP, minimizes recycling challenges and promotes sustainability. Made from polyolefin materials without metal components, APF Futurity supports the global shift towards eco-friendly products. The innovative design, based on proven technology, delivers consistent dosing without compromising performance. The product will be unveiled at Pharmapack 2023 in Paris on February 1-2, 2023.

AptarGroup (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, payable on February 23, 2023, to stockholders of record as of February 2, 2023. Additionally, a conference call is scheduled for February 17, 2023, at 8:00 a.m. CT to discuss the fourth quarter and year-end results for 2022. The company also announced that the 2023 Annual Meeting of Stockholders will take place virtually on May 3, 2023, at 9:00 a.m. CT, with a record date of March 10, 2023. For further details, visit www.aptar.com.

AptarGroup, Inc. (NYSE: ATR), based in Crystal Lake, Illinois, announced its quarterly conference call schedule for 2023. Key dates include:

• Q4 2022 on February 16, 2023 (call on February 17, 2023, at 8:00 a.m. CT)
• Q1 2023 on April 27, 2023 (call on April 28, 2023, at 8:00 a.m. CT)
• Q2 2023 on July 27, 2023 (call on July 28, 2023, at 8:00 a.m. CT)
• Q3 2023 on October 25, 2023 (call on October 26, 2023, at 8:00 a.m. CT)

Press releases will follow after the close of trading on the NYSE.

AptarGroup, Inc. (NYSE: ATR), a leader in drug delivery and consumer product dispensing, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:45 p.m. EST. Key executives, including President and CEO Stephan Tanda, will be present. The presentation will be accessible on the company's Investors page. Aptar operates globally, providing innovative solutions for various markets, including pharmaceuticals and beauty. The company is headquartered in Crystal Lake, Illinois, employing 13,000 staff across 20 countries.

AptarGroup, Inc. (NYSE: ATR) announced a realignment of its business reporting segments, effective January 1, 2023. The new segments, Aptar Closures and Aptar Beauty, aim to streamline operations and enhance customer focus. The Aptar Closures segment will consolidate closures expertise to broaden market reach, while Aptar Beauty will focus on complex dispensing solutions for various markets. The company will continue to report on three segments, including Aptar Pharma, and will disclose recast historical financials prior to its first quarter results.

AptarGroup (NYSE: ATR) has been recognized as one of the World's Top Female-Friendly Companies for 2022 by Forbes, placing 70th out of 400 companies. This marks the second consecutive year Aptar has received this honor, highlighting its commitment to promoting an inclusive workplace culture. The recognition stemmed from an independent survey of 85,000 women across 36 countries, evaluating companies on employee support and leadership diversity. Aptar's Board features 40% women, while 37% of its executive committee are female.

AptarGroup, Inc. (NYSE:ATR) reported a 15% increase in net income to $54 million for Q3 2022, with sales up 1% to $837 million. Core sales, excluding currency and acquisitions, rose 9%. The Pharma segment led growth with a 20% core sales increase, benefiting from rising demand in prescription and healthcare markets. Beauty + Home saw 4% growth in Europe, while Food + Beverage remained flat due to weaker demand and inventory adjustments. Aptar expects Q4 EPS between $0.73 to $0.83, amid ongoing inflationary pressures and expected declines in certain markets.

Aptar Digital Health has partnered with Chiesi Group to launch a comprehensive disease management platform targeting asthma and COPD. This initiative aims to empower patients and enhance healthcare delivery through data-driven insights. The economic burden of respiratory diseases in Europe is significant, costing around €40 billion. The partnership focuses initially on Europe, with plans for future expansions. Key stakeholders emphasized the potential to improve patient experiences and sustainability in healthcare.